Company Analysis Vir Biotechnology, Inc.
1. Summary
Advantages
- Price (9.11 $) is less than fair price (11.16 $)
- The stock's return over the last year (-11.64%) is higher than the sector average (-37.33%).
Disadvantages
- Dividends (0%) are below the sector average (0.5399%).
- Current debt level 6.35% has increased over 5 years from 0.0463%.
- The company's current efficiency (ROE=-38.68%) is lower than the sector average (ROE=9.39%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Vir Biotechnology, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -10.9% | -1.7% | -1.9% |
| 90 days | 5.4% | -40.1% | 2.7% |
| 1 year | -11.6% | -37.3% | 26.1% |
VIR vs Sector: Vir Biotechnology, Inc. has outperformed the "Healthcare" sector by 25.69% over the past year.
VIR vs Market: Vir Biotechnology, Inc. has significantly underperformed the market by -37.72% over the past year.
Stable price: VIR is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: VIR with weekly volatility of -0.2238% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (9.11 $) is lower than the fair price (11.16 $).
Price significantly below the fair price: The current price (9.11 $) is 22.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (6.56) is lower than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (6.56) is lower than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.8595) is lower than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (0.8595) is lower than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (15.86) is lower than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (15.86) is higher than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.93) is higher than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.93) is lower than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 21.18% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (21.18%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (-38.68%) is lower than that of the sector as a whole (9.39%).
ROE vs Market: The company's ROE (-38.68%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (-31.38%) is lower than that of the sector as a whole (0.1519%).
ROA vs Market: The company's ROA (-31.38%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (85.04%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (85.04%) is higher than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 02.12.2024 | de Verneuil Vanina EVP and General Counsel |
Sale | 8.22 | 625 | 76 |
| 03.04.2024 | De Backer Marianne Chief Executive Officer |
Sale | 9.46 | 690 533 | 72 995 |
| 29.06.2023 | SVF Endurance (Cayman) Ltd 10% Owner |
Sale | 25.18 | 2 264 740 | 89 942 |
| 28.06.2023 | SVF Endurance (Cayman) Ltd 10% Owner |
Sale | 25.1 | 175 951 | 7 010 |
| 04.05.2023 | SVF Endurance (Cayman) Ltd 10% Owner |
Sale | 25.55 | 2 921 180 | 114 332 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
